BVT Put 140 NVO 17.01.2025/ DE000VD7RKA7 /
8/9/2024 7:52:13 PM | Chg.-0.350 | Bid9:19:19 AM | Ask9:19:19 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.360EUR | -20.47% | 1.400 Bid Size: 33,000 |
1.410 Ask Size: 33,000 |
Novo Nordisk | 140.00 - | 1/17/2025 | Put |
GlobeNewswire
6/28
SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteri...
GlobeNewswire
6/24
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American ...
GlobeNewswire
6/18
Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesit...
GlobeNewswire
6/18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
6/17
Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Share...
GlobeNewswire
6/13
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Chil...
GlobeNewswire
6/11
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
6/10
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
GlobeNewswire
5/31
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire
5/30
Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire
5/15
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...